Cargando…
Correction: Narongkiatikhun et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac(®) and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. Vaccines 2023, 11, 175
Autores principales: | Narongkiatikhun, Phoom, Noppakun, Kajohnsak, Chaiwarith, Romanee, Winichakoon, Poramed, Vongsanim, Surachet, Suteeka, Yuttitham, Pongsuwan, Karn, Kusirisin, Prit, Wongsarikan, Nuttanun, Fanhchaksai, Kanda, Khamwan, Chantana, Dankai, Dararat, Ophascharoensuk, Vuddhidej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611367/ https://www.ncbi.nlm.nih.gov/pubmed/37897029 http://dx.doi.org/10.3390/vaccines11101538 |
Ejemplares similares
-
Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac(®) and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study
por: Narongkiatikhun, Phoom, et al.
Publicado: (2023) -
WCN23-1041 IMMUNOGENICITY AND SAFETY OF HOMOLOGOUS CHADOX1 NCOV-19 AND HETEROLOGOUS PRIME-BOOST OF CORONAVAC AND CHADOX1 NCOV-19 AMONG KIDNEY TRANSPLANT RECIPIENTS: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY
por: Narongkiatikhun, P., et al.
Publicado: (2023) -
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
por: Winichakoon, Poramed, et al.
Publicado: (2023) -
Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial
por: Noppakun, Kajohnsak, et al.
Publicado: (2021) -
Circulating mitochondrial dysfunction as an early biomarker for contrast media‐induced acute kidney injury in chronic kidney disease patients
por: Kusirisin, Prit, et al.
Publicado: (2023)